GlobalData projects the total revenue from branded infectious diseases (ID) drugs and vaccines to surpass $75bn in 2017. Bolstered by their growing human immunodeficiency virus (HIV) portfolios, Gilead Sciences and ViiV Healthcare – of which GlaxoSmithKline (GSK) owns a majority stake – were the leading players, together totaling almost $38bn in ID drug sales in 2017.
Vaccines were the best-selling products for three of the top 10 companies (Merck, Pfizer and Sanofi) in 2017, with Pfizer being the only top 5 company in the ID space with just a single $1bn product.
Go deeper with GlobalData
From an indication perspective, HIV and hepatitis C continued to drive growth for the ID space. With two of the top five and five of the top 10 sellers in 2017, HIV was by far the most lucrative segment of the ID market, accounting for over 45% of top-20 product sales.
Meanwhile, Gilead’s hepatitis C drugs Harvoni (sofosbuvir/ledipasvir) and Epclusa (sofosbuvir/velpatasvir) cracked the top 5 despite overall declining revenue across the hepatitis C space. Vaccines, led by Pfizer’s Prevnar franchise, accounted for over 30% of top 20 ID product sales in 2017.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
GSK Limited
GSK plc
Gilead Sciences Inc
ViiV Healthcare UK Ltd